Quotient Investors’s Ionis Pharmaceuticals IONS Stock Holding History

Quotient Investors’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-14,700	Closed	-$910K	–	226
2015 Q4	$910K	Buy	+14,700	New	+$793K	0.35%	86
2015 Q2	–	Sell	-5,000	Closed	-$318K	–	266
2015 Q1	$318K	Buy	+5,000	New	+$339K	0.04%	192

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Quotient Investors's IONS Position: Q1 2016 in Review

Quotient Investors sold out of Ionis Pharmaceuticals (IONS) in Q1 2016, closing a stake of 14,700 shares — an estimated $910K sold.

Quotient Investors first reported a position in IONS in Q1 2015 and held it in 2 quarters. The position peaked at $910K in Q4 2015. 314 funds tracked by Wall St. Rank hold IONS as of Q1 2016.

Quotient Investors reported no remaining Ionis Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Quotient Investors sold 14,700 Ionis Pharmaceuticals shares in Q1 2016, an estimated $910K.
Quotient Investors first reported a position in Ionis Pharmaceuticals in Q1 2015 and held it in 2 quarters.
Quotient Investors's Ionis Pharmaceuticals position peaked at $910K in Q4 2015.
314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2016.

Based on Quotient Investors's 13F filing for Q1 2016, filed 14 Apr 2016.